Pan Cancer Liquid Biopsy
A minimally invasive NGS-based assay that analyzes circulating tumor DNA from a plasma sample to detect somatic mutations and gene fusions, enabling real-time therapy monitoring when tissue biopsy is unavailable or impractical.
Clinical Insight
Pan Cancer Testing
The Pan Cancer Liquid Biopsy is a next-generation sequencing assay that analyzes circulating tumor DNA shed into the bloodstream, offering a minimally invasive alternative to traditional tissue biopsy. Using a simple plasma sample, the test identifies somatic mutations and gene fusions relevant to cancer diagnosis, treatment selection, and disease monitoring.
This approach is particularly valuable for patients whose tumors are difficult to biopsy, or when repeated sampling is needed to track treatment response over time. Because it captures genomic information shed by tumors throughout the body, the assay can also detect emerging resistance mutations early, allowing clinicians to adjust treatment strategies promptly and support more responsive, personalized cancer care.
Clinical Applications
Identifies somatic mutations in circulating tumor DNA, revealing cancer-specific genomic changes that inform diagnosis, prognosis, and treatment selection across multiple cancer types.
Clinical Applications
Detects clinically relevant gene fusions from plasma-derived ctDNA, uncovering actionable rearrangements that support targeted therapy selection without invasive tissue sampling procedures.
A germline NGS-based genetic test that identifies inherited variants in cancer predisposition genes, including BRCA1, BRCA2, and extended hereditary panels, enabling early risk assessment and truly personalized preventive care planning today.
Identifies emerging resistance mutations as they develop, enabling timely treatment adjustments before disease progression becomes clinically apparent or symptomatic.
Testing Benefits
Clinical Benefits Of Liquid Biopsy
Minimally Invasive Testing
Requires only a plasma sample rather than surgical or needle-based tissue biopsy, reducing patient discomfort and procedural risk.
Real-Time Treatment Monitoring
Enables ongoing tracking of circulating tumor DNA levels, giving clinicians timely insight into how a patient is responding to therapy.
Alternative To Tissue Biopsy
Provides a reliable testing option for patients whose tumors are difficult to access or biopsy through conventional methods.
Extensive Genomic Detection
Captures somatic mutations and gene fusions from a single plasma sample, offering broad molecular insight relevant to multiple cancer types.
Early Resistance Identification
Detects emerging resistance mutations as they arise, supporting proactive treatment adjustments before disease progression advances.
Repeatable Low-Risk Sampling
Allows for repeated testing over time without the risks associated with multiple tissue biopsies, supporting longitudinal disease tracking.
Schedule Your Test
Reach out to our specialists to arrange liquid biopsy testing and receive dedicated support at every step.
